GLP-3 RTA (Triple G) is a triple incretin receptor agonist simultaneously targeting glucagon like peptide 1 (GLP-1), glucose dependent insulinotropic polypeptide (GIP), and glucagon receptors. The most advanced incretin based research compound in CSD’s metabolic peptide range. F40 Biotech’s 40mg adjustable dose pen delivers this triple receptor agonist in a prefilled pen system with dose adjustment capability, a distinct delivery format from both the lyophilized vial presentations and fixed dose pen systems in CSD’s GLP-3 RTA range, providing researchers with the administration convenience of a pen format combined with the dosing flexibility typically associated with reconstitute vial preparations.

The adjustable dose pen format serves a specific research purpose within CSD’s GLP-3 RTA family. Fixed dose pen systems and lyophilized vials each present trade offs between administration convenience and dosing flexibility. The adjustable dose pen addresses both simultaneously, allowing researchers to dial precise dose increments from a single pen supply without reconstitution preparation while maintaining the ability to modify administered dose across the protocol timeline. This is particularly relevant for triple incretin agonist research where dose titration beginning at lower concentrations and escalating based on observed receptor response is a common protocol design approach in metabolic and appetite regulation research examining GLP-1, GIP, and glucagon receptor co activation thresholds.

CSD’s GLP-3 RTA range now spans the most comprehensive concentration and format selection of any incretin agonist compound in our catalogue: lyophilized vials across Hudson Science 20mg, 30mg, 50mg, 60mg and iLab Pharma 40mg, alongside this F40 Biotech 40mg adjustable dose pen. The adjustable dose pen format sits alongside the lyophilized vial options as a complementary rather than competing presentation. Our vials serving in vitro applications and precise reconstitution controlled protocols, the adjustable pen serving repeated parenteral administration research where dose titration flexibility and preparation free convenience are the priority variables.

F40 Biotech formulations are stocked by Canada Steroid Depot following the same rigorous third party lab verification process applied to every product in our range. Each batch is tested for concentration accuracy and purity before being made available, with COA documentation available on request. CSD’s sourcing standards apply uniformly across all manufacturers we carry, and F40 Biotech’s GLP-3 RTA Triple G pen meets those standards consistently. All orders ship discreetly across Canada in plain, unmarked packaging with no identifying information on the exterior.

Store at 2–8°C away from direct light. Do not freeze. Keep upright. Intended for research purposes only.

Commonly researched alongside dual incretin agonist compounds and Semaglutide in comparative receptor pathway and metabolic activity studies. Browse CSD’s full peptide range for complete sourcing.